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Abstract
Introduction: Recent publications suggest potential benefits from statins as a preventive or adjuvant therapy in
sepsis. Whether ongoing statin therapy should be continued or discontinued in patients admitted in the intensive
care unit (ICU) for sepsis is open to question.
Methods: We retrospectively compared patients with severe sepsis and septic shock in whom statin therapy had
been discontinued or continued. The primary endpoint was the number of organ failure-free days at day 14.
Secondary end-points included hospital mortality and safety. The association of statin continuation with outcome
was evaluated for crude analysis and after propensity score matching and adjustment. We also measured plasma
atorvastatin concentrations in a separate set of ICU septic patients continuing the drug.
Results: Patients in whom statin therapy had been continued in the ICU (n = 44) had significantly more organ
failure-free days (11 [6-14] vs. 6 [0-12], mean difference of 2.34, 95%CI from 0.47 to 5.21, P = 0.03) as compared to
others (n = 32). However, there were important imbalances between groups, with more hospital-acquired
infections, more need for surgery before ICU admission, and a trend towards more septic shock at ICU admission
in the discontinuation group. The significant association of statin continuation with organ failure free days found in
the crude analysis did not persist after propensity-matching or multivariable adjustment: beta coefficients [95% CI]
of 2.37 [-0.96 to 5.70] (P = 0.20) and 2.24 [-0.43 to 4.91] (P = 0.11) respectively. We found particularly high pre-dose
and post-dose atorvastatin concentrations in ICU septic patients continuing the drug.
Conclusions: Continuing statin therapy in ICU septic patients was not associated with reduction in the severity of
organ failure after matching and adjustment. In addition, the very high plasma concentrations achieved during
continuation of statin treatment advocates some caution.
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Introduction
Statins are effective lipid-lowering agents that have been
shown to improve survival in the primary and secondary
prevention of atherosclerosis in several large randomized
clinical trials [1]. Many experimental models have also
shown pleiotropic activity of statins (including anti-
inflammatory, anti-oxidative, and immunomodulatory
effects) that may account for a potential beneficial
impact during sepsis [2,3]. A recent systematic review
and meta-analysis of 20 clinical studies suggests that sta-
tins may have a positive impact on the outcome of
patients with infection or sepsis [4]. Since January 2006
[2], we encouraged continuation of ongoing statin ther-
apy whenever possible in patients chronically treated
with statins who were admitted to our ICU with severe
sepsis, although current prescribing guidelines still sug-
gest caution in the continued use of statins in patients
hospitalized for acute illness because of concern of ser-
ious side effects [5].
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The aim of this preliminary report was: to evaluate the
effectiveness and safety of statin therapy continuation on
the incidence of organ failure in septic patients (com-
pared with patients in whom statins were routinely
stopped); and to assess atorvastatin plasma concentra-
tions during its continuation in a subset of ICU septic
patients.
Materials and methods
The study was approved by the institutional ethics com-
mittee of the “Société de Réanimation de Langue Fran-
çaise”. Informed consent was waived and written and
oral information about the study was given to the
families.
Patients
We conducted a retrospective cohort study among
patients admitted between January 2005 and August
2007 for severe sepsis and septic shock in our ICU and
with ongoing statin therapy (initiated at least one month
before ICU admission and continued with no interrup-
tion until ICU admission). Severe sepsis or septic shock
was defined according to the ACCP/SCCM (American
College of Chest Physicians/Society of Critical Care
Medicine) Consensus Conference [6]. Non-inclusion cri-
teria included a moribund state, an anticipated ICU stay
of less than 24 hours, a contraindication to enteral statin
therapy administration (intolerance to enteral feeding
with vomiting), liver dysfunction with aminotransferase
enzymes (either aspartate or alanine) more than three
times the upper limit of normal (ULN), rhabdomyolysis
with creatine phosphokinase (CPK) levels above five
ULN, myopathy, status epilepticus, concomitant admin-
istration of azole derivatives, delavirdine, or
telithromycin.
Discontinuation and continuation groups
In the first period (January to December 2005), routine
discontinuation of ongoing statin therapy at admission
of septic patients to our ICU was recommended. The
second period (January to December 2006) was an over-
lap period during which the decision to continue or dis-
continue ongoing statin therapy was left to the clinician
in charge of the patient. During the third period (Janu-
ary to August 2007), routine continuation of ongoing
statin therapy was encouraged. Consecutive patients
with severe sepsis and septic shock were retrospectively
identified from January 2005 to August 2007 using the
unit computerized database and data collected by man-
ual chart review. Two groups of septic patients were dis-
tinguished: the discontinuation group (patients in whom
statins were stopped at ICU admission); and continua-
tion group (patients in whom statins were continued
whenever possible). Patients in both groups were
managed in the ICU according to current recommenda-
tions [7].
Statin continuation protocol
“Continuation” patients received their usual statin ther-
apy orally (or via an oro-gastric tube, after crushing the
tablets) in the same dosage as used during ambulatory
care, while conforming to several other precautions as
follows: i) the association with certain medications was
avoided (oral anticoagulants, fibrates and cyclosporine
for all statins, erythromycin, clarithromycin, or verapa-
mil for atorvastatin and simvastatin); ii) if the patient
received enteral feeding via an oro-gastric tube, gastric
residue evaluations were performed at least six hours
after drug administration. Possible side effects of statins
were monitored, by reviewing daily blood chemistry as
well as aminotransferase and CPK levels when available.
Statin therapy was interrupted in the following cases:
food intolerance with vomiting, aminotransferase eleva-
tion above three ULN, increase in serum CPK levels to
above five ULN. In case of interruption of statin therapy
because of food intolerance, the treatment was reintro-
duced after 24 hours of resumption of enteral feeding
without vomiting. The analysis was performed on an
intention-to-treat basis (i.e., patients in the continuation
group remained in that group even if statins were sec-
ondarily discontinued during ICU stay).
Study of atorvastatin plasma concentrations
We prospectively assessed atorvastatin pharmacokinetics
during its continuation (in accordance with the above
mentioned statin continuation protocol) in nine ICU
patients admitted for severe sepsis or septic shock dur-
ing the year 2008 (these patients are not included in the
above mentioned retrospective cohort analysis). A total
of 11 daily administrations of 40 mg of atorvastatin
were assessed for plasma concentrations (two patients
were assessed twice). Blood samples were collected pre-
dose and at 90 minutes post-dose. Demographic data
and information on concurrent medications that might
interact with the cytochrome P450 3A4 enzyme system
were collected. After centrifugation, plasma was stored
frozen at -80°C until analysis. Samples were analysed by
High Performance Liquid Chromatography (Thermo-
Fisher Scientific, Waltham, USA) using ultraviolet detec-
tion at 245 nm (Waters, Saint-Quentin, France) [8]. The
mobile phase was NaH2PO4 10 mM pH5.5/ACN (67/33,
v/v), and thiopental was used as internal standard. Stan-
dard calibration curves for atorvastatin were linear over
concentrations ranging from 20 to 200 ng/mL (average
r2 of 0.99). The limit of quantification was 20 ng/mL.
Intraday precision was good with a coefficient of varia-
tion of 15.3%, 6.0%, and 3.2% for three levels of control
25, 75, and 150 ng/mL. Interday precision was also
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acceptable with coefficient of variation of 18%, 7.1%, and
5.7%, respectively. Accuracy was correct with error per-
centages of 5.1%, 2.0%, and 2.5%, respectively, for the
three controls.
Endpoints
The primary endpoint was the number of organ failure-
free days up to day 14. Secondary end-points included
the number of hemodynamic failure-free days and organ
dysfunction-free days up to day 14, ICU and hospital
survival, and evaluation of treatment safety, assessed as
the proportion of patients with serum CPK above three
ULN and of patients with a transaminases level above
two ULN. Organ dysfunction and organ failure were
defined by a Sequential Organ Failure Assessment
(SOFA) score for the appropriate function above one
and above two, respectively [9]. Hemodynamic failure
was defined by a cardiovascular SOFA score above two
(dopamine > 5 μg/kg/min, norepinephrine regardless of
the dose and adrenaline regardless of the dose) [10].
Organ failure-free days were defined as the number of
days between ICU admission (day 1) and day 14 with
the patient alive without any organ failure. Organ fail-
ure-free days were considered equal to zero in case of
ICU death before day 14. Patients with unavailable
SOFA score (because of ICU discharge before day 14)
were considered free from organ failure after ICU dis-
charge. We also assessed the pre-dose and post-dose
plasma atorvastatin concentrations during its
continuation.
Statistical analysis
Statistical analysis was performed using SPSS Base 17.0
package (SPSS Inc, Chicago, IL, USA) and the nonran-
dom package 1.1 using R 2.10.1 (The R Foundation for
Statistical Computing, Vienna, Austria) [11]. Dichoto-
mous variables are reported as percentage and com-
pared using the Chi-square test or exact Fisher test
(when the expected count was < 5). Quantitative vari-
ables are reported as median (1st quartile to 3rd quartile)
and compared using the nonparametric Mann-Whitney
test. In addition, we used standardized differences to
estimate the balance in measured variables between con-
tinuation and discontinuation groups, independently of
the sample size and variable unit [12].
We used propensity score analyzes to better scrutinize
the association of statin continuation with the primary
outcome (organ failure free days). The rationale and
methods underlying the use of propensity scores for
proposed causal exposure variables have been previously
described [13,14]. The selection of covariates included
in the multivariable logistic regression model used to
estimate the propensity score for statin continuation
was guided by clinical significance and imbalances
between continuation and discontinuation groups, as
estimated by an absolute standardized difference above
20% and/or a relative effect above five (relative effect is
a measure describing the extent to which a covariate is
confounding the effect of statin continuation on out-
come). The final propensity score model included the
following covariates: simplified acute physiology score
(SAPS) II score at ICU admission, SOFA score at ICU
admission, prior statin therapy duration, surgery treat-
ment before ICU admission, septic shock at ICU admis-
sion, infection site, causative organism, type of infection
(community acquired vs. hospital acquired), low-dose
corticosteroid treatment, and fiscal year of ICU admis-
sion (in order to consider potential ongoing temporal
changes in sepsis-related outcomes in our unit). We
matched patients with statin continuation to those with
statin discontinuation, using a greedy-matching algo-
rithm with a calliper width of 0.2 standard deviations of
the log odds of the estimated propensity score and sam-
pling without replacement [15]. We used a graphical
representation with standardized differences to check
the balance of covariates in the matched sample [14]. In
addition to propensity score matching, we performed a
direct adjustment for confounding using a traditional
linear regression model, with the same items selected
for the propensity score as covariates and organ failure
free days as the dependent variable [16]. A P value less
than 0.05 was considered significant in bilateral analysis.
Results
Patients
During the study-period, 81 patients receiving chronic
statin therapy were hospitalized for severe sepsis or sep-
tic shock in our ICU. Five patients were excluded from
the study because of non-inclusion criteria at ICU
admission (vomiting in two patients and rhabdomyolysis
in two others) or insufficient data (one patient; Figure
1). Statins were discontinued upon admission to the
ICU in 32 patients (17 in 2005 and 15 in 2006, none in
2007) and continued in 44 patients (7 in 2005, 23 in
2006, and 14 in 2007). Table 1 and Table 2, respectively,
display patients’ and infection characteristics at ICU
admission. Patients in the discontinuation group had
significantly more hospital-acquired infections, more
need for surgery before ICU admission, and a trend
towards more septic shock at ICU admission as com-
pared with the continuation group.
Outcomes
Patient outcomes in the entire cohort are reported in
Table 3. The numbers of organ failure-free, hemody-
namic failure-free, and organ dysfunction-free days were
significantly higher in the continuation group as com-
pared with the discontinuation group. The need for
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invasive mechanical ventilation and prevalence of acute
respiratory distress syndrome were also significantly
higher in the discontinuation group as compared with
the continuation group. There was a trend towards
increased hospital mortality and hospital length of stay
in the discontinuation group as compared with the con-
tinuation group.
Of the 44 patients who continued statin therapy, 43%
(19) were matched using the propensity score to a simi-
lar patient in whom statins were discontinued. The cov-
ariate balance between the continuation and
discontinuation groups improved substantially through
propensity-score matching (Figure 2). The association of
statin continuation with organ failure-free days was not
significant with the propensity-score matching (Table 4
and Figure 3) or with the linear regression adjustment
(Table 5 and Figure 3).
Safety of statin continuation
Two patients in the continuation group required cessa-
tion of enteral diet and statin administration for 48 hours
because of food intolerance with vomiting. Multiple
blood concentrations of CPK and aminotransferases were
available in 55 (72%) and 63 (83%) patients, respectively
(representing 27% and 43% of patient-days in ICU for the
continuation group, respectively). The proportion of
patients with rhabdomyolysis (CPK levels increase above
five ULN) or increase of liver enzymes (aminotransferases
increase above three ULN) did not differ between the dis-
continuation and continuation groups: 3 (14%) vs. 1 (3%),
P = 0.15; and 6 (25%) vs. 7 (18%), P = 0.54, respectively.
Atorvastatin plasma concentrations during treatment
continuation
We found very high pre-dose and post-dose atorvastatin
concentrations during treatment continuation (up to day
4), with median values of 66 (29-101) and 142 (96-237)
ng/mL, respectively. Six of the nine patients explored
were receiving known cytochrome P450 3A4 inhibitors
(including midazolam, hydrocortisone, amiodarone, and
tacrolimus; Table 6). These patients exhibited higher
atorvastatin concentrations as compared with those not
receiving such inhibitors: 70 (57-105) vs. 29 (27-35) ng/
mL for pre-dose concentration (P = 0.05) and 199 (134-
255) vs. 96 (80-99) ng/mL for post-dose concentration
(P = 0.04), respectively (Figure 4).
Discussion
Our study suggests that the lesser morbidity associated
with continuation of ongoing statin therapy (as com-
pared with systematic discontinuation) in patients with
severe sepsis or septic shock may be influenced by con-
founders. We did not find clear evidence of poor clinical
tolerance of statins, but the plasma concentrations
achieved during continuation of atorvastatin were parti-
cularly high.
A potential beneficial effect of statins during sepsis
has been suggested by several studies reporting both a
Figure 1 Flow-chart of the study population.
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Table 1 Characteristics of 76 patients with severe sepsis and septic shock according to discontinuation or not of





P value Absolute standardized difference* (%)
Age, years 71.1 (61.7-78.7) 72.9 (62.3-79.6) 0.66 7.7
Male gender, n (%) 26 (81%) 33 (75%) 0.52 15.0
SAPS II at ICU admission 44 (34-62) 40 (32-51) 0.15 37.5
SOFA at ICU admission 8 (5-10) 7 (4-9) 0.21 31.0
Mac Cabe classification,** n (%) 0.13 6.8
Nonfatal or no underlying disease 15 (47%) 18 (41%)
Ultimately fatal underlying disease 13 (41%) 25 (57%)
Rapidly fatal underlying disease 4 (13%) 1 (2%)
Prior statin therapy duration, years (n = 67) 3.5 (1.0-6.3) 5.0 (1.4-7.6) 0.26 31.5
Type of statin, n (%) 0.28 15.4
Atorvastatin 13 (41%) 18 (41%)
Pravastatin 9 (28%) 15 (34%)
Simvastatin 10 (31%) 7 (16%)
Rosuvastatin 0 (0%) 3 (7%)
Fluvastatin 0 (0%) 1 (2%)
Surgery before ICU admission, n (%) 11 (34%) 5 (11%) 0.02 56.1
Septic shock at ICU admission, n (%) 19 (59%) 16 (34%) 0.05 46.7
SAPS, simplified acute physiology score; SOFA, sequential organ failure assessment. *[12] **[32].
Table 2 Infection characteristics of 76 patients with severe sepsis and septic shock according to whether ongoing





P value Absolute standardized difference* (%)
Infection site, n (%) 0.74 13.5
Lung 14 (44%) 17 (39%)
Urinary tract 5 (16%) 7 (16%)
Bloodstream (primary) 4 (13%) 7 (16%)
Others 6 (19%) 5 (11%)
Unknown 3 (9%) 8 (18%)
Causative organism, n (%) 0.19 50.5
Gram-positive cocci
Staphylococcus sp. 2 (6%) 3 (7%)
Streptococcus and Enterococcus sp. 4 (13%) 7 (16%)
Gram-negative bacilli
Enterobacteriaceae sp 7 (22%) 13 (30%)
Other Gram-negative bacilli 4 (13%) 6 (14%)
Other organisms 0 (0%) 2 (5%)
Polymicrobial 12 (38%) 5 (11%)
Negative culture 3 (9%) 8 (18%)
Type of infection, n (%) <0.01 65.5
Community acquired 11 (34%) 29 (66%)
Hospital acquired 21 (66%) 15 (34%)
Adequation of initial antibiotic therapy, n (%) 25 (78%) 34 (77%) 0.93 2.0
Low-dose corticosteroids, n (%) 19 (59%) 18 (41%) 0.11 37.1
Activated protein C, n (%) 2 (6%) 0 (0%) 0.09 35.9
*[12]
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preventive effect on the risk of severe sepsis, as well as a
reduction of morbidity and mortality associated with
sepsis [4,17-19], but with significant heterogeneity
among studies and potential publication bias [4]. The
potential effect of the introduction of statins in sepsis
will be resolved by currently ongoing clinical trials
(NCT00528580, NCT00676897, NCT00452608,
NCT00979121, NCT00450840 and NCT00357123) [20].
However, few publications have studied the effect of the
continuation or discontinuation of statins during severe
sepsis in patients chronically treated with statins.
In our study, patients in whom statins were continued
seemed to have a better outcome compared with the
discontinuation group after crude analysis. Kruger et al
previously reported a particularly high mortality in bac-
teriemic patients in whom chronic statin therapy had
been interrupted at time of the septic episode [21]. In
these patients, the poorer outcomes in the discontinua-
tion group could be due to a possible rebound effect of
statins interruption on inflammatory response [22-24],
but many potential sources of bias not addressed may
confound the interpretation of these results [21].
In our study, there were significant imbalances
between groups that may explain the differences in out-
comes. In particular, patients in whom statins were dis-
continued had a higher prevalence of hospital-acquired
infections and septic shock at ICU admission as com-
pared with others. It is possible that more severely ill
patients, and those with more complex presentation,
might have been less likely to have their statins contin-
ued because their physicians were more focused on
treating immediately life-threatening problems or imple-
menting complex diagnostic procedures. After control-
ling for these selection bias via propensity matching and
multivariable adjustment, there was no significant asso-
ciation between statin continuation and the main out-
come (organ failure-free days). These negative findings
are in line with a recent randomized trial that did not
provide evidence of any beneficial role of continuing
pre-existing statin therapy on sepsis progression and
inflammatory parameters [25].
The absorption and metabolism of statins may vary
widely in ICU patients, especially in those with sepsis,
Table 3 Outcome of 76 patients with severe sepsis and septic shock according to discontinuation or not of ongoing





P value Odds ratio
(95% CI)
Invasive mechanical ventilation, n (%) 23 (72%) 21 (48%) 0.03 0.36 (0.14-0.94)
Duration of invasive mechanical ventilation, days 11 (4-18) 6 (3-20) 0.56
Acute Respiratory Distress Syndrome, n (%) 13 (41%) 8 (18%) 0.03 0.33 (0.12-0.92)
Septic shock during ICU stay, n (%) 24 (75%) 23 (52%) 0.04 0.37 (0.14-0.99)
Organ failure free days* 6 (0-12) 11 (6-14) 0.03
Organ dysfunction free days* 2 (0-10) 10 (3-12) 0.03
Hemodynamic failure free days * 11 (7-13) 14 (10-14) 0.04
ICU length of stay, days (ICU survivors, n = 57) 9 (4-16) 6 (4-10) 0.32
Hospital length of stay, days (hospital survivors, n = 54) 36 (18-54) 24 (12-44) 0.09
ICU deaths, n (%) 10 (31%) 9 (21%) 0.28 0.57 (0.20-1.61)
Hospital deaths, n (%) 13 (41%) 9 (21%) 0.06 0.38 (0.14-1.04)
CI, confidence interval.
*Organ failure free days, organ dysfunction free days, and vasoactive drug free days are calculated at day 14; Organ dysfunction was defined by a sequential
organ failure assessment (SOFA) score above one for the appropriate function; Organ failure was defined by a SOFA score above two for the appropriate
function.
Figure 2 Graphical representation of absolute standardized
differences before and after propensity score matching
comparing covariate values. Imbalance for all variables was
substantially reduced after matching. The 20% cut-off was used to
select variables included in the propensity score. SAPS, simplified
acute physiology score; SOFA, sequential organ failure assessment.
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because of frequent alterations of the digestive tract
function. However, only two patients in our study had
treatment interrupted due to gastric intolerance. We
found very high atorvastatin concentrations in patients
continuing this drug, with a nearly 20-fold increase in
pre-dose concentrations as compared with residual con-
centrations reported in healthy volunteers [26]. These
results are in accordance with those of Kruger et al [26]
who recently reported similarly high plasma concentra-
tions of atorvastatin in ICU septic patients. In the later
report, the peak and residual statin concentrations aver-
aged 84 and 23 ng/mL, respectively, in septic ICU
patients after a single 20 mg atorvastatin dose. Our
report demonstrates even higher residual concentrations
(up to 100 ng/mL) after several days of statin continua-
tion in septic ICU patients. These high concentrations
could be explained by specific pharmacokinetic and
pharmacodynamic considerations in septic conditions,
including increased capillary permeability, changes in
plasma protein binding, and altered liver metabolism by
cytochrome systems. Concomitant treatments by cyto-
chrome P450 3A4 inhibitors may also impair atorvasta-
tin metabolism [27,28]. Accordingly, we found
significantly higher atorvastatin concentrations in
patients receiving such inhibitors as compared with
others.
Severe infection is a theoretical contraindication to
statin administration, because these drugs might
increase the risk of rhabdomyolysis and neuromyopathy
[29]. We did not observe significantly more adverse
events in the continuation group as compared with the
discontinuation group, suggesting an acceptable toler-
ance of statins in the context of severe sepsis. However,
Table 4 Outcome of patients with severe sepsis and septic shock according to discontinuation or not of ongoing





P value Odds ratio
(95% CI)
Invasive mechanical ventilation, n (%) 13 (68%) 10 (53%) 0.32 0.51 (0.14-1.92)
Duration of invasive mechanical ventilation, days 11 (4-18) 6 (4-31) 0.84
Acute Respiratory Distress Syndrome, n (%) 8 (42%) 3 (16%) 0.07 0.26 (0.06-1.19)
Septic shock during ICU stay, n (%) 12 (63%) 13 (68%) 0.72 1.26 (0.33-4.84)
Organ failure free days* 6 (0-12) 9 (6-12) 0.23
Organ dysfunction free days* 1 (0-9) 8 (3-11) 0.11
Hemodynamic failure free days * 11 (7-14) 12 (7-14) 0.65
ICU length of stay, days (ICU survivors, n = 27) 10 (4-17) 6 (5-10) 0.42
Hospital length of stay, days (hospital survivors, n = 25) 29 (14-51) 20 (13-37) 0.45
ICU deaths, n (%) 5 (26%) 6 (32%) 0.72 1.29 (0.32-5.28)
Hospital deaths, n (%) 7 (37%) 6 (32%) 0.73 0.79 (0.21-3.03)
CI, confidence interval.
* Organ failure free days, organ dysfunction free days, and vasoactive drug free days are calculated at day 14; Organ dysfunction was defined by a sequential
organ failure assessment (SOFA) score above one for the appropriate function; Organ failure was defined by a SOFA score above two for the appropriate
function.
Figure 3 Beta regression coefficients with 95% confidence
intervals for the association between statin continuation and
organ failure free days in models with crude analysis (2.84
(0.51 to 5.17), P = 0.02), propensity matching (2.37 (-0.96 to
5.70), P = 0.20) or multivariable adjustment (2.24 (-0.43 to
4.91), P = 0.11). The beta regression coefficient indicates the
difference in mean number of days between continuation and
discontinuation arms.
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aminotransferases and CPK were not systematically
assessed in all patients. In addition, specific evaluation
of ICU acquired myopathy was not carried out and a
lack of elevated levels of circulating CPK does not rule
out structural muscle injury in patients treated with sta-
tins [30]. Finally, the very high plasma atorvastatin con-
centrations during continuation of this drug may raise
concern. Dosage regimens specifically adapted to criti-
cally ill septic patients, with particular attention to drugs
susceptible to metabolic interactions, may need to be
studied.
Our study has some limitations. First, the number
of patients included was small, a situation that
increases the chance of both type 1 and type 2 errors.
Secondly, the design was retrospective, and, despite
propensity matching and multivariable adjustment,
the retrospective cohort design entails a number of
residual biases that cannot be controlled for. Finally,
although the pleiotropic effects of statins may be
observed on longer term [31], our analysis was limited
to the short term.
Conclusions
In conclusion, we found that the apparent beneficial
effects of continuation of chronic statin therapy in septic
ICU patients were driven in part by selection bias and
confounders. Although there was no clear clinical evi-
dence of poor tolerance of statins, the very high plasma
concentrations achieved during continuation of atorvas-
tatin suggest that caution should prevail if statins are
prescribed to septic patients, and their risk/benefit ratio
assessed carefully.
Key messages
• Patients in whom statin therapy had been contin-
ued in the ICU during severe sepsis or septic shock
had significantly more organ failure-free days as
compared with those with statin discontinuation, but
this difference did not persist after propensity score
matching and multivariable adjustment.
• The predose and postdose atorvastatin concentra-
tions were particularly high in septic patients conti-
nuing the drug in the ICU. These very high
Table 5 Multivariable linear regression model for organ failure free days
Coefficient (ß) Standard error 95% confidence interval Wald c2 P value
Intercept 2589 1832
Statin continuation 2.24 1.36 (-0.43, 4.91) 2.71 0.10
SAPS II score at ICU admission -0.10 0.03 (-0.16, -0.04) 9.26 <0.01
SOFA score at ICU admission -0.37 0.27 (-0.90, 0.15) 1.93 0.17
Prior statin therapy duration 0.04 0.17 (-0.29, 0.36) 0.05 0.83
Surgery treatment before ICU admission -1.30 1.64 (-4.52, 1.92) 0.62 0.43
Septic shock at ICU admission 1.90 1.75 (-1.53, 5.32) 1.18 0.28
Infection site 0.46 0.38 (-0.28, 1.19) 1.48 0.22
Polymicrobial infection -3.46 1.55 (-6.49, -0.43) 5.01 0.03
Hospital-acquired infection 1.17 1.41 (-1.59, 3.94) 0.69 0.41
Low-dose corticosteroid treatment -2.04 1.26 (-4.51, 0.44) 2.60 0.11
Year of ICU admission -1.29 0.91 (-3.08, 0.51) 1.98 0.17
SAPS, simplified acute physiology score; SOFA, sequential organ failure assessment.
Table 6 Individual characteristics of nine critically ill septic patients with atorvastatin plasma concentrations
assessment during treatment continuation
Patient Age Diagnosis SAPS II ICU survivor CA MV Feeding Cytochrome P450 3A4 inhibitors
1 89 Undocumented sepsis 46 Yes Yes No Oral No
2 64 Surgical site infection 40 Yes Yes Yes OGT No
3 77 Pneumonia 44 Yes No No Oral No
4 74 Pneumonia 56 No Yes Yes OGT Yes (amiodarone, midazolam, hydrocortisone)
5 81 Cholecystitis 113 No Yes Yes OGT Yes (midazolam, hydrocortisone)
6 62 Pneumonia 54 No Yes Yes OGT Yes (hydrocortisone)
7 60 Urosepsis 35 Yes Yes No Oral Yes (tacrolimus, hydrocortisone)
8 56 Urosepsis 81 Yes Yes Yes OGT Yes (midazolam)
9 67 Liver abscess 67 Yes Yes Yes OGT Yes (amiodarone, midazolam, hydrocortisone)
CA, catecholamine therapy; MV, mechanical ventilation; OGT, oro-gastric tube; SAPS, simplified acute physiology score.
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concentrations advocate some caution when admin-
istering statins to septic patients in the ICU setting.
Abbreviations
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